Kite Pharma Company Profile (NASDAQ:KITE)

About Kite Pharma (NASDAQ:KITE)

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KITE
  • CUSIP: N/A
  • Web:
  • Market Cap: $7.77 billion
  • Outstanding Shares: 57,181,000
Average Prices:
  • 50 Day Moving Avg: $112.38
  • 200 Day Moving Avg: $85.70
  • 52 Week Range: $39.82 - $138.94
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.26
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $32.14 million
  • Price / Sales: 241.87
  • Book Value: $12.43 per share
  • Price / Book: 10.94
  • EBIDTA: ($341,060,000.00)
  • Net Margins: -1,117.44%
  • Return on Equity: -59.56%
  • Return on Assets: -48.86%
  • Current Ratio: 9.01%
  • Quick Ratio: 9.01%
  • Average Volume: 1.10 million shs.
  • Beta: 2.81
  • Short Ratio: 9.16

Frequently Asked Questions for Kite Pharma (NASDAQ:KITE)

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma, Inc. (NASDAQ:KITE) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($1.94) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.97) by $0.03. The business had revenue of $10.10 million for the quarter, compared to analysts' expectations of $9.59 million. Kite Pharma had a negative net margin of 1,117.44% and a negative return on equity of 59.56%. The business's revenue for the quarter was up 110.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.91) EPS. View Kite Pharma's Earnings History.

When will Kite Pharma make its next earnings announcement?

Kite Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Kite Pharma.

Where is Kite Pharma's stock going? Where will Kite Pharma's stock price be in 2017?

16 analysts have issued twelve-month price targets for Kite Pharma's stock. Their forecasts range from $54.00 to $135.00. On average, they anticipate Kite Pharma's share price to reach $89.00 in the next year. View Analyst Ratings for Kite Pharma.

What are analysts saying about Kite Pharma stock?

Here are some recent quotes from research analysts about Kite Pharma stock:

  • 1. Cowen and Company analysts commented, "Competitor Novartis is scheduled to present pivotal data from CTL019’s JULIET trial in." (6/7/2017)
  • 2. Jefferies Group LLC analysts commented, "The NHS published a mock technology appraisal analysis to assess the value of CAR T therapy and determine a value-based price. The study was conducted for young ALL and determined a price of ??530K ($649K) was justified. We view this price as an upper limit for Axi-Cel pricing, and raise our Axi-Cel price estimate to $300K (prev' $200K). We also decreased WACC to 13% (prev 15%) which was offset by moderating share to drive our new PT of $101." (3/16/2017)
  • 3. Canaccord Genuity analysts commented, "The Kochenderfer study for CAR-19 published in the Journal of Clinical Oncology showed 12 months' median duration of complete response, suggesting positive read-through generally speaking for ZUMA-1. Importantly, 11 of 12 complete responses (CRs) are still ongoing, suggesting the potential for very long-term remission. We believe the CAR-19 data suggest that KTE-C19 is a favorable option for NHL patients with few, if any, other treatment options, which may provide long-term potentially curative benefit." (3/15/2017)
  • 4. According to Zacks Investment Research, "Kite Pharma reported narrower-than-expected loss in the fourth quarter of 2016. Despite announcing a lower-than-expected sales guidance for 2017, shares shot up on positive topline results from a key study evaluating axicabtagene ciloleucel, its experimental CAR-T therapy, for treating aggressive non-Hodgkin lymphoma (NHL). The solid efficacy profile demonstrated by the study furthers Kite’s chances of getting the drug approved this year. Kite Pharma is focused on the development of immuno-oncology treatments and is looking to revolutionize cancer treatments by engaging the body’s own immune system to treat cancer. Immuno-oncology is a hot therapeutic area with huge commercial potential.  Meanwhile, after declining in 2016, its shares are picking up in 2017, outperforming the Biomed/Genetics industry. However, there are several other companies working to bring innovative immuno-oncology treatments to market." (3/2/2017)
  • 5. Wedbush analysts commented, "KITE is poised to complete submission of the first BLA for a CAR-T therapy, but we believe slow adoption of the new treatment modality may blunt its first mover advantage, as CAR-T competition matures and treatment strategies evolve to address safety and efficacy challenges." (2/1/2017)

Who are some of Kite Pharma's key competitors?

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the folowing people:

  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

Who owns Kite Pharma stock?

Kite Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (12.13%), Vanguard Group Inc. (7.07%), BlackRock Inc. (7.07%), Capital World Investors (4.50%), Wildcat Capital Management LLC (4.21%) and State Street Corp (3.02%). Company insiders that own Kite Pharma stock include Arie Belldegrun, Cynthia M Butitta, David Bonderman, David D Chang, Farah Champsi, Helen Susan Kim, Jeffrey Wiezorek, Marc Better, Margo R Roberts, Owen N Witte, Paul L Jenkinson, Rizwana F Sproule, Roy Doumani, Shawn Tomasello, Steven B Ruchefsky and Timothy L Moore. View Institutional Ownership Trends for Kite Pharma.

Who sold Kite Pharma stock? Who is selling Kite Pharma stock?

Kite Pharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, Menora Mivtachim Holdings LTD., Royal Bank of Canada, First Trust Advisors LP, BB Biotech AG, Migdal Insurance & Financial Holdings Ltd. and American Century Companies Inc.. Company insiders that have sold Kite Pharma stock in the last year include Arie Belldegrun, Cynthia M Butitta, David D Chang, Farah Champsi, Helen Susan Kim, Jeffrey Wiezorek, Owen N Witte, Roy Doumani, Shawn Tomasello, Steven B Ruchefsky and Timothy L Moore. View Insider Buying and Selling for Kite Pharma.

Who bought Kite Pharma stock? Who is buying Kite Pharma stock?

Kite Pharma's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., State Street Corp, Capital World Investors, Capital Research Global Investors, Northern Trust Corp, Spark Investment Management LLC and Wildcat Capital Management LLC. Company insiders that have bought Kite Pharma stock in the last two years include Arie Belldegrun, David Bonderman and Paul L Jenkinson. View Insider Buying and Selling for Kite Pharma.

How do I buy Kite Pharma stock?

Shares of Kite Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kite Pharma's stock price today?

One share of Kite Pharma stock can currently be purchased for approximately $135.95.

MarketBeat Community Rating for Kite Pharma (NASDAQ KITE)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  560 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  780
MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Kite Pharma (NASDAQ:KITE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $89.00 (34.53% downside)

Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Stifel NicolausReiterated RatingHold$74.00LowView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingBuy$121.00 -> $135.00LowView Rating Details
8/9/2017Canaccord GenuitySet Price TargetBuy$115.00 -> $120.00MediumView Rating Details
7/13/2017Maxim GroupDowngradeBuy -> Hold$88.00LowView Rating Details
7/4/2017Roth CapitalReiterated RatingBuy$93.00MediumView Rating Details
7/4/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
6/16/2017WedbushReiterated RatingUnderperform$54.00LowView Rating Details
6/8/2017BTIG ResearchUpgradeNeutral -> Buy$100.00HighView Rating Details
5/30/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/19/2017HC WainwrightReiterated RatingBuy$85.00MediumView Rating Details
5/15/2017Raymond James Financial, Inc.DowngradeOutperform -> Mkt PerformN/AView Rating Details
5/9/2017Goldman Sachs Group, Inc. (The)Boost Price TargetBuy$85.00 -> $89.00HighView Rating Details
3/13/2017Standpoint ResearchDowngradeBuy -> Hold$85.00LowView Rating Details
3/6/2017Royal Bank Of CanadaBoost Price TargetOutperform$85.00 -> $95.00N/AView Rating Details
3/2/2017Citigroup Inc.DowngradeBuy -> Neutral$62.00 -> $87.00N/AView Rating Details
2/22/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
9/27/2016Barclays PLCBoost Price TargetEqual Weight$60.00 -> $65.00N/AView Rating Details
8/9/2016MizuhoSet Price TargetBuy$80.00N/AView Rating Details
3/20/2016SunTrust Banks, Inc.Reiterated RatingBuy$70.00N/AView Rating Details
(Data available from 8/22/2015 forward)


Earnings History for Kite Pharma (NASDAQ:KITE)
Earnings by Quarter for Kite Pharma (NASDAQ:KITE)
Earnings History by Quarter for Kite Pharma (NASDAQ KITE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($2.14)N/AView Earnings Details
8/8/2017Q2 2017($1.97)($1.94)$9.59 million$10.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.68)($1.74)$8.85 million$9.80 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.75)($1.70)$5.74 million$4.90 millionViewListenView Earnings Details
11/9/2016Q316($1.68)($1.49)$4.94 million$7.34 millionViewListenView Earnings Details
8/8/2016Q216($1.21)($0.91)$4.86 million$4.80 millionViewN/AView Earnings Details
5/9/2016Q116($1.08)($0.90)$4.61 million$5.10 millionViewN/AView Earnings Details
2/29/2016Q4($0.71)($0.85)$4.54 million$4.89 millionViewListenView Earnings Details
11/12/2015Q315($0.64)($0.63)$4.06 million$5.10 millionViewListenView Earnings Details
8/10/2015Q215($0.41)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details
5/15/2015Q115$1.16($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details
3/26/2015Q414($0.16)($0.33)ViewN/AView Earnings Details
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Kite Pharma (NASDAQ:KITE)
2017 EPS Consensus Estimate: ($7.72)
2018 EPS Consensus Estimate: ($8.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($1.79)($1.36)($1.60)
Q2 20175($1.93)($1.53)($1.76)
Q3 20175($2.26)($1.91)($2.09)
Q4 20175($2.49)($2.00)($2.27)
Q1 20182($2.26)($1.90)($2.08)
Q2 20182($2.26)($1.76)($2.01)
Q3 20182($2.21)($1.83)($2.02)
Q4 20182($1.96)($1.82)($1.89)
(Data provided by Zacks Investment Research)


Dividend History for Kite Pharma (NASDAQ:KITE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Kite Pharma (NASDAQ:KITE)
Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 83.94%
Insider Trades by Quarter for Kite Pharma (NASDAQ:KITE)
Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)
Insider Trades by Quarter for Kite Pharma (NASDAQ:KITE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2017Cynthia M ButittaCOOSell15,000$120.72$1,810,800.00View SEC Filing  
8/10/2017Helen Susan KimEVPSell6,251$120.09$750,682.59View SEC Filing  
8/8/2017Helen Susan KimEVPSell79,949$119.56$9,558,702.44View SEC Filing  
8/3/2017Timothy L MooreEVPSell6,000$110.06$660,360.00View SEC Filing  
8/1/2017Timothy L MooreEVPSell12,000$107.69$1,292,280.00View SEC Filing  
7/31/2017Helen Susan KimEVPSell26,649$109.28$2,912,202.72View SEC Filing  
7/10/2017Cynthia M ButittaCOOSell15,000$103.09$1,546,350.00View SEC Filing  
7/3/2017Jeffrey WiezorekSVPSell10,000$104.32$1,043,200.00View SEC Filing  
6/26/2017Owen N WitteDirectorSell25,000$100.30$2,507,500.00View SEC Filing  
6/23/2017Cynthia M ButittaCOOSell5,000$100.81$504,050.00View SEC Filing  
6/16/2017Farah ChampsiDirectorSell20,450$89.79$1,836,205.50View SEC Filing  
6/14/2017Steven B RuchefskyDirectorSell20,000$89.48$1,789,600.00View SEC Filing  
6/9/2017Cynthia M ButittaCOOSell10,000$88.55$885,500.00View SEC Filing  
6/8/2017Roy DoumaniDirectorSell15,000$84.48$1,267,200.00View SEC Filing  
5/10/2017Paul L. JenkinsonCFOBuy3,450$72.59$250,435.50View SEC Filing  
5/9/2017Arie BelldegrunChairmanBuy17,000$68.57$1,165,690.00View SEC Filing  
5/9/2017David BondermanDirectorBuy50,000$68.94$3,447,000.00View SEC Filing  
5/1/2017David D ChangEVPSell20,000$82.09$1,641,800.00View SEC Filing  
4/28/2017Farah ChampsiDirectorSell19,168$82.75$1,586,152.00View SEC Filing  
4/26/2017Farah ChampsiDirectorSell123,913$82.67$10,243,887.71View SEC Filing  
4/25/2017Cynthia M ButittaCOOSell15,000$81.85$1,227,750.00View SEC Filing  
4/25/2017Farah ChampsiDirectorSell46,783$82.80$3,873,632.40View SEC Filing  
4/24/2017Farah ChampsiDirectorSell25,818$82.34$2,125,854.12View SEC Filing  
4/17/2017Farah ChampsiDirectorSell115,376$82.42$9,509,289.92View SEC Filing  
4/3/2017Cynthia M ButittaCOOSell5,000$81.96$409,800.00View SEC Filing  
4/3/2017Helen Susan KimEVPSell2,400$81.80$196,320.00View SEC Filing  
3/27/2017Cynthia M ButittaCOOSell10,000$77.67$776,700.00View SEC Filing  
3/9/2017Cynthia M ButittaCOOSell21,118$80.78$1,705,912.04View SEC Filing  
3/1/2017Cynthia M ButittaCOOSell38,882$73.46$2,856,271.72View SEC Filing  
3/1/2017Helen Susan KimEVPSell50,300$67.78$3,409,334.00View SEC Filing  
3/1/2017Jeffrey WiezorekSVPSell18,000$75.01$1,350,180.00View SEC Filing  
3/1/2017Roy DoumaniDirectorSell18,800$74.46$1,399,848.00View SEC Filing  
2/27/2017Cynthia M ButittaCOOSell10,000$54.42$544,200.00View SEC Filing  
1/31/2017Cynthia M ButittaCOOSell10,000$50.56$505,600.00View SEC Filing  
1/6/2017Cynthia M ButittaCOOSell10,000$50.13$501,300.00View SEC Filing  
1/6/2017Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
12/20/2016Arie BelldegrunChairmanSell3,493$50.86$177,653.98View SEC Filing  
12/20/2016Cynthia M ButittaCOOSell2,482$50.86$126,234.52View SEC Filing  
12/20/2016David D. ChangEVPSell1,788$50.86$90,937.68View SEC Filing  
12/20/2016Jeffrey WiezorekSVPSell716$50.86$36,415.76View SEC Filing  
12/20/2016Shawn TomaselloInsiderSell4,901$50.86$249,264.86View SEC Filing  
12/1/2016Jeffrey WiezorekSVPSell1,500$50.76$76,140.00View SEC Filing  
11/25/2016Cynthia M ButittaCOOSell10,000$50.40$504,000.00View SEC Filing  
10/3/2016Jeffrey WiezorekSVPSell1,500$54.81$82,215.00View SEC Filing  
9/26/2016Cynthia M ButittaCOOSell10,000$54.13$541,300.00View SEC Filing  
9/1/2016Jeffrey WiezorekSVPSell1,500$58.24$87,360.00View SEC Filing  
8/25/2016Cynthia M. ButittaCOOSell10,000$58.28$582,800.00View SEC Filing  
8/15/2016Helen Susan KimEVPSell35,900$60.27$2,163,693.00View SEC Filing  
8/1/2016Jeffrey WiezorekSVPSell1,500$56.90$85,350.00View SEC Filing  
7/25/2016Cynthia M ButittaCOOSell10,000$50.94$509,400.00View SEC Filing  
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00View SEC Filing  
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00View SEC Filing  
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.00View SEC Filing  
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00View SEC Filing  
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.00View SEC Filing  
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.38View SEC Filing  
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.00View SEC Filing  
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00View SEC Filing  
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.92View SEC Filing  
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.36View SEC Filing  
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.00View SEC Filing  
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.00View SEC Filing  
2/1/2016Marc BetterVPSell9,000$47.34$426,060.00View SEC Filing  
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.00View SEC Filing  
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.83View SEC Filing  
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.00View SEC Filing  
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.90View SEC Filing  
1/4/2016Marc BetterVPSell9,000$61.53$553,770.00View SEC Filing  
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.00View SEC Filing  
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.00View SEC Filing  
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.00View SEC Filing  
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.20View SEC Filing  
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.71View SEC Filing  
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.00View SEC Filing  
11/2/2015Marc BetterVPSell9,000$71.07$639,630.00View SEC Filing  
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.00View SEC Filing  
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.00View SEC Filing  
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.65View SEC Filing  
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.86View SEC Filing  
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.00View SEC Filing  
10/1/2015Marc BetterVPSell9,000$54.81$493,290.00View SEC Filing  
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.00View SEC Filing  
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.85View SEC Filing  
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.12View SEC Filing  
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.00View SEC Filing  
9/1/2015Marc BetterVPSell9,000$51.81$466,290.00View SEC Filing  
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.00View SEC Filing  
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Kite Pharma (NASDAQ:KITE)
Latest Headlines for Kite Pharma (NASDAQ:KITE)
DateHeadline logoBreakfast Technical Briefing on Biotech Stocks -- Kite Pharma, Novavax, Sangamo Therapeutics, and Spectrum Pharma - PR Newswire (press release) - August 21 at 8:39 AM logoKite Pharma (KITE) Highlights Publication from NCI Demonstrating Responses in Patients with Metastatic Solid Tumors ... - - August 18 at 6:11 AM logoKite Pharma: Sky's The Limit - Benzinga - August 17 at 1:12 AM logoHC Wainwright Reiterates "Buy" Rating for Kite Pharma, Inc. (KITE) - August 16 at 8:56 AM logoKite Pharma, Inc. (KITE) EVP Helen Susan Kim Sells 6,251 Shares - August 14 at 10:46 PM logoCynthia M. Butitta Sells 15,000 Shares of Kite Pharma, Inc. (KITE) Stock - August 14 at 10:30 PM logoQ3 2017 EPS Estimates for Kite Pharma, Inc. (KITE) Lifted by Wedbush - August 11 at 10:45 AM logoKite Pharma, Inc. (KITE) to Post Q3 2017 Earnings of ($2.26) Per Share, Jefferies Group Forecasts - August 11 at 9:12 AM logoHelen Susan Kim Sells 79,949 Shares of Kite Pharma, Inc. (NASDAQ:KITE) Stock - August 10 at 7:26 PM logoKite Pharma, Inc. to Post Q3 2017 Earnings of ($2.19) Per Share, SunTrust Banks Forecasts (NASDAQ:KITE) - August 10 at 7:06 AM logoKite Pharma (KITE) Q2 Loss Narrower than Expected, Sales Beat - Nasdaq - August 10 at 12:20 AM logoKite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up - Nasdaq - August 10 at 12:20 AM logoKite Pharma, Inc. (NASDAQ:KITE) Stock Rating Reaffirmed by Jefferies Group LLC - August 9 at 9:10 PM logoKite Pharma, Inc. (KITE) Expected to Earn Q1 2018 Earnings of ($2.26) Per Share - August 9 at 12:08 PM logoKite Pharma, Inc. (NASDAQ:KITE) Expected to Post Quarterly Sales of $9.23 Million - August 9 at 7:20 AM logoEdited Transcript of KITE earnings conference call or presentation 8-Aug-17 12:30pm GMT - August 9 at 1:03 AM logoKite Pharma, Inc. (KITE) Issues Quarterly Earnings Results - August 8 at 3:48 PM logoBRIEF-Kite announces initiation of axicabtagene ciloleucel CAR-T clinical program in EU - August 8 at 12:39 AM logoKite Pharma (KITE) Initiates Axicabtagene Ciloleucel CAR-T Clinical Program in EU - August 8 at 12:39 AM logoKite Pharma, Inc. (KITE) Expected to Announce Earnings of -$1.97 Per Share - August 7 at 8:14 PM logoKite Pharma (KITE) Initiates Axicabtagene Ciloleucel CAR-T Clinical Program in EU - - August 7 at 7:38 PM logoForm 4 Kite Pharma, Inc. For: Aug 03 - August 5 at 7:03 PM logoWhat's in the Cards for Kite Pharma (KITE) in Q2 Earnings - August 5 at 12:03 AM logoKite Pharma, Inc. (NASDAQ:KITE) EVP Timothy L. Moore Sells 6,000 Shares - August 4 at 10:32 PM logoKite Pharma, Inc. (KITE) Receives Consensus Recommendation of "Buy" from Analysts - August 4 at 10:44 AM logoForm 4 Kite Pharma, Inc. For: Aug 01 Filed by: MOORE TIMOTHY L. - - August 4 at 4:14 AM logoKite Announces Landmark Study of Refractory Aggressive Non ... - Business Wire (press release) - August 3 at 11:13 PM logoTimothy L. Moore Sells 12,000 Shares of Kite Pharma, Inc. (KITE) Stock - August 3 at 10:38 PM logoForm 4 Kite Pharma, Inc. For: Jul 31 - - August 3 at 1:47 AM logoKite Pharma (KITE) Doses First Patient in Phase 2 Trial of Axicabtagene Ciloleucel in iNHL - - August 3 at 1:47 AM logoHelen Susan Kim Sells 26,649 Shares of Kite Pharma, Inc. (KITE) Stock - August 1 at 7:28 PM logoKite Pharma (KITE) Files MAA in Europe for Axicabtagene Ciloleucel - - July 31 at 7:38 PM logoCommit To Buy Kite Pharma At $75, Earn 9.9% Using Options - Nasdaq - July 26 at 3:35 PM logoKite Pharma, Inc. (NASDAQ:KITE) Downgraded by Vetr Inc. - July 25 at 12:14 AM logoWedbush Comments on Kite Pharma, Inc.'s Q2 2017 Earnings (KITE) - July 24 at 7:10 AM logoToday's Research Reports on Stocks to Watch: Sarepta Therapeutics and Kite Pharma - July 22 at 5:20 AM logoBrokers Issue Forecasts for Kite Pharma, Inc.'s FY2021 Earnings (NASDAQ:KITE) - July 21 at 4:42 PM logoKite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the ... - July 21 at 5:45 AM logoKite Pharma (KITE) Highlights Publishing of Results Showing ... - - July 21 at 12:45 AM logoKite Pharma, Inc. (NASDAQ:KITE) Expected to Post Quarterly Sales of $9.69 Million - July 20 at 11:12 AM logoKite Pharma, Inc. (KITE) Upgraded at Vetr Inc. - July 18 at 12:27 AM logoIs Juno Therapeutics Stock Still a Strong Buy? - Motley Fool - July 14 at 5:52 AM logoKite Pharma, Inc. (NASDAQ:KITE) Lowered to Hold at Maxim Group - July 13 at 4:08 PM logoEquities Analysts Set Expectations for Kite Pharma Inc's Q2 2017 Earnings (NASDAQ:KITE) - July 12 at 7:38 AM logoFDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma - Barron's - July 12 at 1:55 AM logoCynthia M. Butitta Sells 15,000 Shares of Kite Pharma, Inc. (NASDAQ:KITE) Stock - July 11 at 7:52 PM logoFDA panel to focus on safety of Novartis gene therapy drug - July 11 at 1:18 AM logoKite Pharma, Inc. (KITE) Price Target Raised to $121.00 - July 10 at 12:20 PM logoCanaccord Genuity Reiterates Buy Rating for Kite Pharma, Inc. (KITE) - July 10 at 11:38 AM logoKite Pharma, Inc. (KITE) Receives Average Rating of "Buy" from Analysts - July 10 at 10:38 AM



Kite Pharma (KITE) Chart for Tuesday, August, 22, 2017

This page was last updated on 8/22/2017 by Staff